FY2026 EPS Estimate for AngioDynamics Boosted by Analyst

AngioDynamics, Inc. (NASDAQ:ANGO) – Investment analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for shares of AngioDynamics in a report issued on Monday, April 6th. HC Wainwright analyst Y. Chen now expects that the medical instruments supplier will earn ($0.15) per share for the year, up from their previous forecast of ($0.28). The consensus estimate for AngioDynamics’ current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for AngioDynamics’ Q1 2027 earnings at ($0.05) EPS, Q2 2027 earnings at ($0.03) EPS and FY2027 earnings at ($0.03) EPS.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Thursday, April 2nd. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 4.66% and a negative net margin of 10.01%.The firm had revenue of $78.42 million for the quarter, compared to analysts’ expectations of $76.77 million.

Other equities analysts have also recently issued reports about the company. Canaccord Genuity Group decreased their target price on AngioDynamics from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Monday. Wall Street Zen cut AngioDynamics from a “buy” rating to a “hold” rating in a report on Sunday, December 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a report on Wednesday, January 21st. Freedom Capital raised AngioDynamics to a “strong-buy” rating in a report on Monday. Finally, Zacks Research cut AngioDynamics from a “strong-buy” rating to a “hold” rating in a report on Monday, March 30th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.67.

AngioDynamics Stock Performance

Shares of AngioDynamics stock opened at $9.70 on Wednesday. AngioDynamics has a one year low of $8.36 and a one year high of $13.99. The stock’s fifty day moving average is $10.83 and its 200 day moving average is $11.54. The stock has a market cap of $399.83 million, a P/E ratio of -12.93 and a beta of 0.43.

Institutional Trading of AngioDynamics

Several institutional investors have recently made changes to their positions in ANGO. Essex Investment Management Co. LLC grew its position in shares of AngioDynamics by 41.9% during the third quarter. Essex Investment Management Co. LLC now owns 327,396 shares of the medical instruments supplier’s stock worth $3,657,000 after purchasing an additional 96,639 shares in the last quarter. Bastion Asset Management Inc. grew its position in shares of AngioDynamics by 31.8% during the third quarter. Bastion Asset Management Inc. now owns 1,264,003 shares of the medical instruments supplier’s stock worth $13,442,000 after purchasing an additional 304,960 shares in the last quarter. Divisadero Street Capital Management LP grew its position in shares of AngioDynamics by 8.3% during the third quarter. Divisadero Street Capital Management LP now owns 3,678,125 shares of the medical instruments supplier’s stock worth $41,085,000 after purchasing an additional 282,695 shares in the last quarter. Acuitas Investments LLC grew its position in shares of AngioDynamics by 12.7% during the third quarter. Acuitas Investments LLC now owns 498,530 shares of the medical instruments supplier’s stock worth $5,569,000 after purchasing an additional 56,300 shares in the last quarter. Finally, State of Wyoming grew its position in shares of AngioDynamics by 53.6% during the third quarter. State of Wyoming now owns 4,749 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 1,658 shares in the last quarter. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics News Summary

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: HC Wainwright materially raised near- and medium-term EPS forecasts for ANGO (multiple notes boosting Q1/Q2 FY2027 and FY2026–FY2027 estimates), signaling improving fundamentals and expected narrowing losses. HC Wainwright Upgrades
• Positive Sentiment: Freedom Capital upgraded AngioDynamics to a “strong-buy,” which supports bullish sentiment among some investors. Freedom Capital Upgrade
• Positive Sentiment: Recent quarterly results showed AngioDynamics beat revenue and EPS expectations and narrowed its loss, driven by Med Tech demand — a near-term operational positive even as gross margin declined. Q3 Earnings Beat
• Neutral Sentiment: Analyst consensus still expects a negative full-year EPS (around -$0.37), so while estimates are improving, the company is not yet profitable on a full-year basis — a caution for risk-sensitive investors. Consensus Estimates
• Negative Sentiment: Canaccord Genuity lowered its price target on ANGO from $18 to $16 (but kept a Buy rating). The PT cut can weigh on short-term sentiment and is likely a driver of today’s weaker share performance. Price Target Cut

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.